Releases

Media coverage

Newsletter

Subscribe to our newsletter

Archive


Jun 1, 2014

Norsk tekst lenger ned

Sunday June 1st Lytix Biopharma presents results from the first Phase I clinical study with LTX-315 at the 50th annual ASCO (American Society of Clinical Oncology). The results are presented as a poster at the ‘Developmental Therapeutics - Immunotherapy Poster Session’. The poster title is “A Phase I study with LTX-315 – an immunogenic cell death inducer in patients with transdermally accessible tumours”. ASCO is the largest clinical cancer congress, with participants from all over the world.

The overall conclusions from the study were:

  • The main safety issues were primarily dose-related flushing and transient hypotension
  • Tumour infiltrating lymphocytes and tumour regression were observed in some patients
  • The findings confirms the rationale and potential benefit of LTX-315 as a novel intralesional immunotherapy
  • A Phase I/IIa study with LTX-315 is ongoing at four sites in Europe (ClinicalTrials.gov NCT01986426)

See the poster here

 

Norsk tekst

Søndag 1.juni presenteres resultatene fra den første LTX-315-Fase 1-studien på den årlige ASCO-konferansen (American Society of Clinical Oncology). Dataene fra studien presenteres som poster på ‘Developmental Therapeutics – Immunotherapy Poster Session’. Tittelen på posteren er “A Phase I study with LTX-315 – an immunogenic cell death inducer in patients with transdermally accessible tumours”. ASCO er verdens største kliniske kreftkongress, med deltakere fra alle land.

Hovedkonklusjonene fra studien var følgende:

  • Det viktigste sikkerhetsfunnet var dose-relatert rødming i huden og forbigående blodtrykksfall
  • Tumorinfiltrerende lymfocytter og reduksjon av den behandlede kreftsvulsten ble observert i noen pasienter
  • Disse resultatene bekrefter rasjonale for og den potensielle nytten av LTX-315 som en ny i-tumor immunterapi
  • En Fase 1/2a-studie med LTX-315 pågår nå ved fire kreftsykehus i Europa (ClinicalTrials.gov NCT01986426)

Se posteren her